Aspergillus to zygomycetes: Causes, risk factors, prevention, and treatment of invasive fungal infections

Infection

Volumn 36, Issue 4, 2008, Pages 296-313

  Cornely, O A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIVIRUS AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLOSIS; ASPERGILLUS; CANCER CHEMOTHERAPY; CANDIDA; CANDIDIASIS; CHILL; CLINICAL TRIAL; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; FEBRILE NEUTROPENIA; FEVER; FUSARIUM; HUMAN; HYPOKALEMIA; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE REACTION; LIVER TOXICITY; MONOTHERAPY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; REVIEW; RIGOR; ZYGOMYCETES;

EID: 50649101461     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7357-z     Document Type: Review

References (200)

1. Mahfouz T, Anaissie E: Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003; 4: 974-990.
2. Clark TA, Hajjeh RA: Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569-574.
3. Perea S, Patterson TF: Endemic mycoses. In: Anaissie EJ, McGinnis MR, Pfaller MA (eds). Clinical mycology. Churchill Livingstone, Philadelphia 2003.
4. Galgiani JN: Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med 1999; 130: 293-300.
5. Blair JE: Coccidioidomycosis in liver transplantation. Liver Transpl 2006; 12: 31-39.
6. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M: Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
7. Hope WW, Walsh TJ, Denning DW: Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609-622.
8. Verweij PE, Mennink-Kersten MASH: Issues with galactomannan testing. Med Mycol 2006; 44: S179-S183.
9. Marr KA, Patterson T, Denning D: Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875-894.
10. Denning DW: Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
11. Prentice HG, Kibbler CC, Prentice AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-284.
12. Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
13. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE: Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003; 24: 477-482.
14. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A: Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272.
15. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
16. Lemos LB, Soofi M, Amir E: Blastomycosis and pregnancy. Ann Diagn Pathol 2002; 6: 211-215.
17. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
18. Chiller TM, Galgiani JN, Stevens DA: Coccidioidomycosis. Infect Dis Clin North Am 2003; 17: 41-57.
19. Rosenstein NE, Emery KW, Werner SB, Kao A, Johnson R, Rogers D, Vugia D, Reingold A, Talbot R, Plikaytis BD, Perkins BA, Hajjeh RA: Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis 2001; 32: 708-715.
20. Franca AVC, Carneiro M, dal Sasso K, da Silva Souza C, Martinelli A: Cryptococcosis in cirrhotic patients. Mycoses 2005; 48: 68-72.
21. Friedman GD, Fessel WJ, Udaltsova NV, Hurley LB: Cryptococcosis: the 1981-2000 epidemic. Mycoses 2005; 48: 122-125.
22. Husain S, Wagener MM, Singh N: Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7: 375-381.
23. Perfect JR, Casadevall A: Cryptococcosis. Infect Dis Clin North Am 2002; 16: 837-874v-vi.
24. Tintelnot K, Lemmer K, Losert H, Schar G, Polak A: Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses 2004; 47: 455-464.
25. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S: Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4: 183-188.
26. Zonios DI, Falloon J, Huang C-Y, Chaitt D, Bennett JE: Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007; 86: 78-92.
27. Revankar SG, Sutton DA, Rinaldi MG: Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38: 206-216.
28. LaRocco A Jr, Netzer RC: Central venous catheters as a risk factor for disseminated phaeohyphomycosis? Clin Infect Dis 2002; 35: 1022-1023.
29. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34: 467-476.
30. Kantarcioglu AS, de Hoog GS: Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses 2004; 47: 4-13.
31. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V, Bodey G: The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988; 67: 77-83.
32. Boutati EI, Anaissie EJ: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
33. Lionakis MS, Kontoyiannis DP: Fusarium infections in critically ill patients. Semin Respir Crit Care Med 2004; 25: 159-169.
34. Nelson PE, Dignani MC, Anaissie EJ: Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7: 479-504.
35. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, Mangini C, Simoes BP, Colombo AL, Vaz J, Levy CE, Costa S, Moreira VA, Oliveira JS, Paraguay N, Duboc G, Voltarelli JC, Maiolino A, Pasquini R, Souza CA: Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98: 315-319.
36. Wheat LJ, Kauffman CA: Histoplasmosis. Infect Dis Clin North Am 2003; 17: 1-19vii.
37. Kauffman CA: Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20: 115-132.
38. Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, Melillo L, Buelli M, Pizzarelli G, Venditti M, Martino P, and the GIMEMA Infection Program: Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818-1828.
39. Chayakulkeeree M, Ghannoum MA, Perfect JR: Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-229.
40. Gonzalez CE, Rinaldi MG, Sugar AM: Zygomycosis. Infect Dis Clin North Am 2002; 16: 895-914vi.
41. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
42. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
43. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
44. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA: Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
45. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-1110.
46. Ampel NM: Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005; 41: 1174-1178.
47. Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K, Wagener MM, Singh N: Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
48. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E: Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-1242.
49. Mocherla S, Wheat LJ: Treatment of histoplasmosis. Semin Respir Infect 2001; 16: 141-148.
50. Herbrecht R, Neuville S, Letscher-Bru V, Natarajan-Ame S, Lortholary O: Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment. Drugs Aging 2000; 17: 339-351.
51. Singh N, Paterson DL: Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
52. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
53. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP: Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
54. Koch S, Hohne FM, Tietz HJ: Incidence of systemic mycoses in autopsy material. Mycoses 2004; 47: 40-46.
55. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A: Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37: 934-936.
56. Subramanian S, Mathai D: Clinical manifestations and management of cryptococcal infection. J Postgrad Med 2005; 51: S21-S26.
57. Clancy CJ, Singh N: Dematiaceous fungi: (Chromoblastomycosis, Mycetoma, Phaeohyphomycosis). In: Yu V, Reiner W, Raoult D (eds). Antimicrobial therapy and vaccines, 2nd edition Apple Trees Productions LLC, New York 2002.
58. Sanche SE, Sutton DA, Rinaldi MG: Dematiaceous fungi. In: Anaissie EJ, McGinnis MR, Pfaller MA (eds). Clinical mycology. Churchill Livingstone, Philadelphia 2003.
59. Milam CP, Fenske NA: Chromoblastomycosis. Dermatol Clin 1989; 7: 219-225.
60. Revankar SG: Phaeohyphomycosis. Infect Dis Clin North Am 2006; 20: 609-620.
61. Jahagirdar BN, Morrison VA: Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002; 17: 113-120.
62. Torres HA, Raad II, Kontoyiannis DP: Infections caused by Fusarium species. J Chemother 2003; 15: 28-35.
63. Girmenia C, Pagano L, Corvatta L, Mele L, Del Favero A, Martino P, For The Gimema Infection Programme The epidemiology of fusariosis in patients with haematological diseases. Br J Haematol 2000; 111: 272-276.
64. Freifeld AG, Iwen PC, Lesiak BL, Gilroy RK, Stevens RB, Kalil AC: Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005; 7: 109-115.
65. Espinel-Ingroff A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
66. Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K: Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002; 35: E35-E36.
67. Akagi T, Yamaguti K, Kawamura T, Nakumura T, Kubo K, Takemori H: Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk Lymphoma 2006; 47: 1182-1183.
68. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M: Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42: 753-757.
69. Ribes JA, Vanover-Sams CL, Baker DJ: Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
70. Ibrahim A, Edwards A Jr, Gebremariam T, Fu Y, Spellberg B: The iron chelator, deferasirox (Exjade), protects mice from mucormycosis. In: Abstracts from the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA 2006.
71. Ellis D: Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002; 49: 7-10.
72. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM: In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006 ; 50: 2009-2015.
73. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, Lee J, Callender D, Rubin M, Pizzo PA: Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616-1622.
74. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG: In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345.
75. Gilgado F, Serena C, Cano J, Gene J, Guarro J: Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006; 50: 4211-4213.
76. Gallis HA, Drew RH, Pickard WW: Amphotericin B:30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
77. Deray G: Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49: 37-41.
78. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, and the L Amph/ABLC Collaborative Study Group A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-1163.
79. Cornely OA, Vehreschild JJ, Ullmann AJ: Is there a role for polyenes in treating invasive mycoses? Curr Opin Infect Dis 2006; 19: 565-570.
80. O'Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, Ito J, Nademanee A, Niland J, Parker P, Smith EP: Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827-834.
81. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, Peters WP: Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891-897.
82. Rousey SR, Russler S, Gottlieb M, Ash RC: Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484-492.
83. Ascioglu S, De Pauw BE, Meis JFGM: Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int J Antimicrob Agents 2000; 15: 159-168.
84. Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC: Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000; 25: 879-884.
85. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
86. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, Mufti GJ: Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-168.
87. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR: Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8: 13-20.
88. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995; 59: 45-50.
89. Shah T, Lai WK, Gow P, Leeming J, Mutimer D: Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 2005; 7: 126-132.
90. Castroagudin JF, Ponton C, Bustamante M, Otero E, Martinez J, Tome S, Conde R, Segade FR, Delgado M, Brage A, Galban C, Varo E: Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005; 37: 3965-3967.
91. Drew RH, Dodds Ashley ES, Benjamin DK Jr, Davis RD, Palmer SM, Perfect JR: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-237.
92. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddemann W, Siegert W, Beyer J: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661.
93. EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-672.
94. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771.
95. Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M, for the Study Group of the Paul Ehrlich Society A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 2006; 34: 118-126.
96. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, Sylvester R, Meis J, Boogaerts M, Selleslag D, Krcmery V, von Sinner W., MacDonald P, Doyen C, Vandercam B: An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406-1412.
97. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
98. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, van Burik JA, Laverdiere M, Safrin S, Wingard JR: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366.
99. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE: Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137: 105-109.
100. Perfect JR: Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40: S401-S408.
101. Fichtenbaum CJ, German M, Dunagan WC, Fraser VJ, Medoff G, Diego J, Powderly WG: A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis 1999; 29: 1551-1556.
102. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28: 73-82.
103. Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JR: Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993; 7: 829-835.
104. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-718.
105. Lortholary O, Denning DW, Dupont B: Endemic mycoses: a treatment update. J Antimicrob Chemother 1999; 43: 321-331.
106. Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, Corvatta L, D'Antonio D, Girmenia C, Martino P, Del Favero A, for the GIMEMA Infection Program: Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214.
107. Arenas R:Chromoblastomycosis. Antifungal drug therapy. A complete guide for the practitioner. In: Marcel Dekker Inc, New York, 1990, pp.
108. Maenza JR, Merz WG: Infections caused by non-Candida, non-Cryptococcus yeasts. In: Anaissie EJ, McGinnis MR, Pfaller MA (eds). Clinical mycology. Churchill Livingstone, Philadelphia 2003.
109. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.
110. Gallagher JC, MacDougall C, Dodds Ashley ES, Perfect JR: Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Rev Anti Infect Therapy 2004; 2: 253-268.
111. Perea S, Patterson TF: Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-1080.
112. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
113. Sendid B, Cotteau A, Francois N, D'Haveloose A, Standaert A, Camus D, Poulain D: Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80.
114. Marr KA, White TC, van Burik JA, Bowden RA: Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25: 908-910.
115. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
116. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
117. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, and The Canadian Fluconazole Prophylaxis Study Group Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331-340.
118. Playford EG, Webster AC, Sorrell TC, Craig JC: Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006; 25: 549-561.
119. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, Matsuyama T, Takezako N, Miwa A, Kern W, Kami M, Akiyama H, Hirai H, Togawa A: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-1625.
120. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282-289.
121. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, Fanci R, Menichetti F, Caselli D, Giacchino M, Congiu M: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32A: 814-820.
122. Cha R, Sobel JD: Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infective Therapy 2004; 2: 357-366.
123. Oude Lashof AM, De Bock R, Herbrecht R, De Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerova H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ, for the EORTC Invasive Fungal Infections Group: An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004; 40: 1314-1319.
124. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, Di Lorenzo G, for the Candida Esophagitis Multicenter Italian Study Group: Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996; 111: 1169-1177.
125. Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, Dismukes WE, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995; 20: 267-271.
126. Catanzaro A, Galgiani JN, Levine BE, Sharkey-Mathis PK, Fierer J, Stevens DA, Chapman SW, Cloud G, and the NIAID Mycoses Study Group: Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995; 98: 249-256.
127. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, Nassar F, Lutz JE, Stevens DA, Sharkey PK, Singh VR, Larsen RA, Delgado KL, Flanigan C, Rinaldi MG, for the National Institute of Allergy and Infectious Diseases-Mycoses Study Group: Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Ann Intern Med 2000; 133: 676-686.
128. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-89.
129. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE: Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
130. Chryssanthou E, Cherif H, Petrini B, Kalin M, Bjorkholm M: Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis 2004; 36: 855-859.
131. Pujol I, Guarro J, Gene J, Sala J: In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39: 163-167.
132. Carrillo AJ, Guarro J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-2153.
133. Prentice AG, Glasmacher A: Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56: i17-i22.
134. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L: Enhanced bioavailability of itraconazole in hydroxypropyl-beta- cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-1865.
135. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
136. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
137. Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C, Pasold R, Wolf HH, Hanel M, Dolken G, Junghanss C, Andreesen R, Bertz H: An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-325.
138. Sharpe MD, Ghent C, Grant D, Horbay GLA, McDougal J, Colby WD: Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003; 76: 977-983.
139. Winston DJ, Busuttil RW: Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74: 688-695.
140. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K, and the Itraconazole Neutropenia Study Group: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135: 412-422.
141. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB: Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
142. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
143. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: e83-e90.
144. Graybill JR, Vazquez J, Darouiche RO, Morhart R, Greenspan D, Tuazon C, Wheat LJ, Carey J, Leviton I, Hewitt RG, MacGregor RR, Valenti W, Restrepo M, Moskovitz BL: Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33-39.
145. Phillips P, De Beule K, Frechette G, Tchamouroff S, Vandercam B, Weitner L, Hoepelman A, Stingl G, Clotet B: A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368-1373.
146. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J: A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227-232.
147. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA, and others in the NAIAD Mycoses Study Group: Itraconazole treatment of coccidioidomycosis. Am J Med 1990; 89: 282-290.
148. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W: Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 100-107.
149. Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
150. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
151. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, Diekema DJ: Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209-212.
152. Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S, Kuentz M, Bretagne S, Ribaud P: Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-948.
153. Wingard JR, Carter SL, Walsh TJ., Kurtzberg J, Small TN, Gersten ID, Mendizabal AM, Leather H, Confer DL, Baden LR, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, DiPersio JF, Boeckh M, Marr KA: Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IF) in 600 allogeneic blood and marrow transplant (BMT) patients. In: Presented at 49th Annual Meeting and Exposition of the American Society of Hematology. Atlanta, GA 2007, 8-11 December 2007.
154. Powers JH, Dixon CA, Goldberger MJ: Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever [letter]. N Engl J Med 2002; 346: 289-290.
155. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
156. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
157. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, Dupont B, Torre-Cisneros J, Just-Nubling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
158. Baden LR, Katz JT, Fishman JA, Koziol C, Del Vecchio A, Doran M, Rubin RH: Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-1637.
159. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454.
160. Spellberg BJ, Filler SG, Edwards JE Jr: Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
161. Hoffman HL, Rathbun RC: Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002; 11: 409-429.
162. Herbrecht R: Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infective Therapy 2004; 2: 485-497.
163. Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
164. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh Y-T, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
165. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, de Morais Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
166. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-666.
167. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik J-AH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
168. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, Hare R, Boparai N, Isaacs R: Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-614.
169. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, Greaves W, Isaacs R: A multicenter, randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-1186.
170. Catanzaro A, Cloud GA, Stevens DA, Levine BE, Williams PL, Johnson RH, Rendon A, Mirels LF, Lutz JE, Holloway M, Galgiani JN: Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45: 562-568.
171. Stevens DA, Rendon A, Gaona-flores V, Catanzaro A, Anstead GM, Pedicone L, Graybill JR: Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132: 952-958.
172. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP: Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403.
173. Restrepo A, Tobon A, Clark B, Graham DR, Corcoran G, Bradsher RW, Goldman M, Pankey G, Moore T, Negroni R, Graybill JR: Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54: 319-327.
174. Keating GM: Posaconazole. Drugs 2005; 11: 1553-1567.
175. Greenberg RN, Mullane K, van Burik J-AH, Raad I, Abzug MJ, Anstead G, Herbrecht R, Langston A, Marr KA, Schiller G, Schuster M, Wingard JR, Gonzalez CE, Revankar SG, Corcoran G, Kryscio RJ, Hare R: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133.
176. van Burik J-AH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-e65.
177. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS, Hardalo CJ: Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56: 745-755.
178. Denning DW: Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
179. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47: 1376-1381.
180. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ, for the National institutes of Allergy and Infectious Diseases Mycoses Study Group: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
181. Cornely OA, Ullmann AJ, Karthaus M: Choosing a study population for the evaluation of antifungal prophylaxis [letter]. Clin Infect Dis 2005; 40: 1699.
182. Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M, Yokozawa T, Baba H, Emi N, Naoe T: Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006; 45: 259-264.
183. Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, Niki Y, Ikemoto H: A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372-379.
184. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JHJ, Rex JH, Lau W, Facklam D, Buell DN: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-661.
185. Kuse E-R, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullman AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, for the Micafungin Invasive Candidiasis Working Group: Micafungin versus lipsomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
186. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH: Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-147.
187. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, de Pauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
188. Kartsonis N, Di Nubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183-187.
189. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, Di Nubile MJ, Sable CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-457.
190. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-1535.
191. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299.
192. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J, for the Caspofungin Invasive Candidiasis Study Group: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
193. Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, Velez J, Williams-Diaz A, Lipka J, Taylor A, Sable C, Kartsonis N: Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-369.
194. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, for the Caspofungin Salvage Aspergillosis Study Group: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
195. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-299.
196. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-775.
197. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T: Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48: 2021-2024.
198. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ, for the Anidulafungin Study Group: Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
199. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012.
200. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007; 45(7): 883-93.